Oramed Pharmaceuticals

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It focuses on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Oramed Pharmaceuticals, Inc. engages in the provision of oral delivery solutions for drugs delivered via injection. It concentrates on the research and development of pharmaceutical solutions, including an oral insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules or pills for delivery of other polypeptides. The company was founded by Nadav Kidron and Miriam Kidron on April 12, 2002 and is headquartered in New York, NY.

NEW YORK , Sept. 6, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview and share the Company's latest updates at the H.C.

Oramed to Present at H.C. Wainwright 24th Annual Global Investment Conference

-  ORA-D-013-2 is the second of two Phase 3 trials under FDA protocol -  ORA-D-013-1, the larger of the two trials, completed enrollment with top line data expected January 2023 NEW YORK , July 26, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that it has enrolled and randomized over 50% of the planned 450 patients for its international multicenter Phase 3 ORA-D-013-2 trial of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D). ORA-D-013-2 is the second of Oramed's two Phase 3 trials being conducted under U.S. Food and Drug Administration (FDA) Investigational New Drug Application (IND) to treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months.

Oramed Reaches 50% Enrollment in its Second Phase 3 Oral Insulin Trial

The biotech's stock has been ripping higher of late.

Why Oramed Pharmaceuticals Stock Is On Fire Today

NEW YORK , July 11, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it will present an in-person company overview and share the Company's latest updates at the Canaccord Genuity Annual Growth Conference, to be held in Boston, Massachusetts from August 8-11, 2022. Presentation Details: Canaccord Genuity Annual Growth Conference Date:               Wednesday, August 10, 2022 Time:               4:30 p.m.

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference

A reassuring letter to shareholders has the biotech's stock jumping today.

Why Oramed Pharmaceuticals Stock Rocketed Higher Today

NEW YORK , June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Anne Peters, MD, to its Scientific Advisory Board. Anne Peters, MD, is Professor of Medicine at the Keck School of Medicine of USC and Director of the USC Clinical Diabetes Programs.

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board

NEW YORK , May 18, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present an in-person company overview at the H.C. Wainwright Global Investment Conference, on May 25, 2022 in Miami, Florida.

Oramed to Present at H.C. Wainwright Global Investment Conference

ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase 3 ORA-D-013-1 study Top line data expected in January 2023 NEW YORK, May 3, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced it has completed patient enrollment for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D), surpassing its target of 675 patients with 710 patients enrolled.    ORA-D-013-1 is the larger of Oramed's two Phase 3 studies being conducted under U.S. Food and Drug Administration (FDA) approved protocols to treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months.

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1

Oramed is developing oral insulin in a phase 3 trial, data this year. Nobody has been able to deliver insulin orally in adequate quantity.

Oramed And Oral Insulin: Can This Small Company Really Do It?

NEW YORK, April 4, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the appointment of Yadin Rozov to its Board of Directors effective April 1, 2022. The Board determined that Mr.

Oramed Appoints Yadin Rozov to its Board of Directors

NEW YORK, March 29, 2022 /PRNewswire/ — Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey commissioned by Oramed from IQVIA, a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry.     The survey included 88 Endocrinologists and 82 Primary Care Physicians in the U.S. and Europe.

Oramed's Diabetes Market Survey Shows Strong Interest for ORMD-0801 Oral Insulin Candidate Among Physicians

NEW YORK, March 22, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that it will host a webinar with Key Opinion Leaders (KOLs) on the need for oral insulin in type 2 diabetes on Wednesday, March 30, 2022, at 12:00 p.m. Eastern Time.

Oramed to Host Key Opinion Leader Webinar on Need for Oral Insulin in Type 2 Diabetes

NEW YORK, March 10, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a live company overview at the Barclays Global Healthcare Conference, to be held in Miami, Florida from March 15-17, 2022. Mr. Kidron's presentation will be on Tuesday, March 15, 2022, at 3:50 p.m.

Oramed to Present at Barclays Global Healthcare Conference

NEW YORK, Jan. 12, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today issued a Letter to Shareholders from its Chief Executive Officer, Nadav Kidron. To see a video message from the CEO please click here: https://www.youtube.com/watch?v=vgq1I7ylKsk Dear Shareholders,  2021 was a defining year for Oramed as we advanced existing programs, added a new significant opportunity to address a major unmet medical need, and strategically positioned our organization to execute on anticipated 2022 milestones and beyond.

Oramed Issues Annual Message to Shareholders

NEW YORK, Jan. 5, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced the European Patent Office has granted the Company a patent titled "Protease Inhibitor-Containing Compositions, Compositions Comprising Same, and Methods for Producing and Using Same." The patent supports Oramed's oral protein delivery platform technology which underlies its lead drug candidate ORMD-0801 now in pivotal Phase 3 studies and positioned to potentially be the first oral insulin capsule on the market.

Oramed Granted Key European Patent for Platform Technology in Oral Delivery of Proteins

MyMD Pharmaceuticals

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. (“Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (“Oramed”), has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax's oral C

MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

Oramed Pharmaceuticals Inc. ORMP, -11.40% said Wednesday its Oravax Medical subsidiary has signed an agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Co. to pre-purchase 10 million doses of Oravax's oral COVID-19 vaccines in development. The drug maker's stock slipped 0.1% in premarket trading.

Oramed's Oravax sub signs pre-purchase agreement for 10 million oral COVID-19 vaccines with Tan Thanh

NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, today announced that its subsidiary, Oravax Medical, has signed a Cooperation and Purchase Agreement with Vietnam-based Tan Thanh Holdings Investment Joint Stock Company to pre-purchase Oravax's oral COVID-19 vaccine, currently in development. The agreement grants Tan Thanh Holdings the right to sell Oravax's oral vaccine in development throughout the Association of Southeast Asian Nations (ASEAN) which includes Vietnam, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines, Singapore and Thailand.

Oramed Subsidiary Oravax Medical Signs Cooperation and Purchase Agreement for an Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccines with Tan Thanh Holdings to Commercialize in Southeast Asia

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its subsidiary, Oravax Medical Inc. (www.ora-vax.com), has screened and enrolled the first participant in a Phase 1 clinical trial of its oral virus-like particle (VLP) COVID-19 vaccine in Johannesburg, South Africa. The open-label trial anticipates enrolling 24 participants who have not received either a COVID-19 vaccine or contracted the virus.

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral COVID-19 Vaccine Trial in South Africa

NEW YORK, Dec. 8, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the appointment of Netanel Derovan to serve as Chief Legal Officer (General Counsel) and Company Secretary, effective January 9, 2022. Mr. Derovan will oversee Oramed's legal and corporate strategy affairs and provide strategic guidance to the executive team and Board of Directors.

Oramed Pharmaceuticals Appoints Chief Legal Officer

NEW YORK, Nov. 24, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery platforms, announced today that its common stock will be added to the MSCI USA Small Cap Index effective Tuesday, November 30th at the close of market. The MSCI USA Small Cap Index is designed to measure the performance of the small cap segment of the U.S. equity market.

Oramed to Join MSCI USA Small Cap Index

NEW YORK, Nov. 23, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has enrolled and randomized over 75% of the 675 patients planned for its Phase 3 ORA-D-013-1 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).   ORA-D-013-1 is the larger of Oramed's two Phase 3 studies being conducted under U.S. Food and Drug Administration (FDA) approved protocols to treat T2D patients who have inadequate glycemic control over a period of 6 to 12 months.

Oramed Reaches 75% Enrollment in Phase 3 Oral Insulin Study

BALTIMORE--(BUSINESS WIRE)--MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. (“Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (“Oramed”), has established a 50–50 joint venture with Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB), a leading pharmaceutical and personal care product

MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

NEW YORK and MEXICO CITY, Nov. 18, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, and Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB) (www.genommalab.com/en/), a leading pharmaceutical and personal care product company in Latin America with an expanding international presence, today announced the formation of a 50/50 joint venture between Genomma Lab and Oramed's majority-owned subsidiary Oravax Medical Inc. (www.ora-vax.com) to develop and commercialize Oravax's oral COVID-19 vaccine candidate in Mexico.

Oramed Subsidiary Oravax Medical and Genomma Lab Internacional Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America

NEW YORK, November 11, 2021 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that Chief Executive Officer Nadav Kidron will present a company overview at the H.C. Wainwright 7th Annual Israel Virtual Conference, on November 15, 2021 at 11:30am Eastern.

News for Oramed Pharmaceuticals Stock (ORMP)